Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Calcium dobesilate is a synthetic small molecule vasoprotective agent and the calcium salt of dobesilic acid. It is primarily used to treat chronic venous insufficiency, varicose veins, hemorrhoids, and microangiopathies such as diabetic retinopathy. Its mechanism of action involves stabilizing capillary walls by reducing their permeability and increasing resistance. This is achieved through stabilization of collagen chains in the basement membrane and modulation of biochemical mediators that regulate endothelial permeability. The drug also improves erythrocyte flexibility, inhibits platelet hyperaggregation, reduces blood viscosity (especially in diabetic retinopathy), and enhances tissue perfusion[1][5][6][7]. These effects help correct capillary dysfunctions due to metabolic or functional disorders.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on calcium dobesilate.